HE4

• HE4 is a protein biomarker, often elevated in epithelial ovarian cancer.
• The HE4 blood test is a simple procedure used to measure its levels.
• It helps in monitoring ovarian cancer recurrence and assessing malignancy risk, especially in conjunction with CA-125.
• High HE4 levels can indicate the presence or recurrence of ovarian cancer, but they are not diagnostic on their own.
• The HE4 test for ovarian cancer is particularly useful in post-menopausal women and for monitoring treatment effectiveness.

What is HE4 (Human Epididymis Protein 4)?

HE4, or Human Epididymis Protein 4, is a protein that is naturally present in healthy tissues, including those of the reproductive and respiratory systems. It belongs to the whey acidic protein (WAP) family and was initially identified in the epididymis, a tube located at the back of the testicle. In a clinical context, what is HE4 refers to its role as a tumor marker, particularly for epithelial ovarian cancer. The protein is overexpressed in various cancers, making it a valuable tool in diagnostic and monitoring strategies.

The HE4 blood test is a simple diagnostic procedure that measures the concentration of HE4 in a patient’s blood serum. It involves a standard blood draw, similar to other routine blood tests. The collected blood sample is then analyzed in a laboratory to determine HE4 levels. This test is often used in conjunction with other biomarkers, such as CA-125, to provide a more comprehensive assessment of a patient’s condition. While HE4 can be elevated in certain benign conditions, its primary clinical utility lies in its association with malignant processes, especially ovarian cancer.

HE4 as an Ovarian Cancer Marker: Understanding Test Results

The role of HE4 as a cancer marker explained primarily revolves around its application in ovarian cancer. It is recognized as a valuable biomarker for monitoring disease progression and recurrence in women diagnosed with epithelial ovarian cancer. Unlike CA-125, which can be elevated in various benign gynecological conditions, HE4 tends to be more specific for epithelial ovarian cancer, especially in early stages and in mucinous or clear cell subtypes where CA-125 may not be significantly elevated. The combination of HE4 and CA-125 is often used in algorithms like the Risk of Ovarian Malignancy Algorithm (ROMA) to help assess the likelihood of malignancy in women with a pelvic mass, particularly in post-menopausal individuals.

Understanding high HE4 levels meaning is crucial for proper interpretation. Elevated HE4 levels can suggest the presence of ovarian cancer or its recurrence, but they are not definitive for diagnosis. Other conditions, such as kidney disease, endometriosis, or certain lung diseases, can also lead to increased HE4 levels. Therefore, HE4 test results must always be interpreted in the context of a patient’s complete clinical picture, including imaging studies, physical examination, and other laboratory tests. For instance, a persistent rise in HE4 levels in a patient undergoing treatment for ovarian cancer may indicate disease progression or recurrence.

The HE4 test for ovarian cancer is particularly beneficial in several scenarios:

• Monitoring Recurrence: For women previously diagnosed with epithelial ovarian cancer, rising HE4 levels can signal disease recurrence earlier than other markers or symptoms.
• Assessing Malignancy Risk: When combined with CA-125 in algorithms like ROMA, HE4 helps distinguish between benign and malignant pelvic masses, especially in post-menopausal women.
• Treatment Response: Declining HE4 levels during chemotherapy or other treatments can indicate a positive response to therapy.

According to the American Cancer Society, ovarian cancer is the fifth leading cause of cancer death among women in the United States, highlighting the importance of effective monitoring tools like HE4. While HE4 is a valuable tool, it is not used for general population screening due to its limited sensitivity and specificity in asymptomatic women. Its primary utility remains in specific clinical contexts to aid in the management and surveillance of ovarian cancer.